UNICREDIT BANK/CALL/NOVO-NORDISK B/1100/0.1/18.12.24 Stock UNICREDIT BANK/CALL/NOVO-NORDISK B/1100/0.1/18.12.24
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/CALL/NOVO-NORDISK B/1100/0.1/18.12.24 Stock

Warrant

DE000HC9ABD1

Market Closed - BOERSE MUENCHEN 15:45:46 2024-06-28 EDT
0.81 EUR -2.41% Intraday chart for UNICREDIT BANK/CALL/NOVO-NORDISK B/1100/0.1/18.12.24
Current month+47.27%
1 month+62.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart NOVO NORDISK A/S
Chart UNICREDIT BANK/CALL/NOVO-NORDISK B/1100/0.1/18.12.24

Latest news about NOVO NORDISK A/S

India plans incentives for diabetes, obesity drug makers in 2026, government official says RE
NOVO NORDISK : UBS gives a Neutral rating ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot MT
More news

Quotes 5-day view

Date Price Change
24-06-28 0.81 -2.41%
24-06-27 0.83 -.--%
24-06-26 0.83 -10.75%
24-06-25 0.93 +27.40%
24-06-24 0.73 -6.41%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 03:45 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
IssuerLogo Issuer UniCredit UniCredit
WKN HC9ABD
ISINDE000HC9ABD1
Date issued 2023-09-18
Strike 1,100 kr
Maturity 2024-12-18 (171 Days)
Parity 10 : 1
Emission price 0.3 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.94 €
Lowest since issue 0.2 €
Delta0x
Omega 0.000000
Premium0x
Gearing17.05x
Moneyness 0.9142
Difference Strike 94.4 kr
Difference Strike %+8.58%
Spread 0.04 €
Spread %4.94%
Intrinsic value 0.000000
Present value 0.7950

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant